BR112018006572A2 - terapia de combinação racional para o tratamento de câncer - Google Patents

terapia de combinação racional para o tratamento de câncer

Info

Publication number
BR112018006572A2
BR112018006572A2 BR112018006572A BR112018006572A BR112018006572A2 BR 112018006572 A2 BR112018006572 A2 BR 112018006572A2 BR 112018006572 A BR112018006572 A BR 112018006572A BR 112018006572 A BR112018006572 A BR 112018006572A BR 112018006572 A2 BR112018006572 A2 BR 112018006572A2
Authority
BR
Brazil
Prior art keywords
combination therapy
cancer treatment
agents
rational combination
chaperone
Prior art date
Application number
BR112018006572A
Other languages
English (en)
Portuguese (pt)
Inventor
Rodina Anna
M Gomes-Dagama Erica
Chiosis Gabriela
Koren John
Shrestha Liza
Taldone Tony
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of BR112018006572A2 publication Critical patent/BR112018006572A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112018006572A 2015-10-05 2016-10-05 terapia de combinação racional para o tratamento de câncer BR112018006572A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562237470P 2015-10-05 2015-10-05
PCT/US2016/055594 WO2017062520A1 (en) 2015-10-05 2016-10-05 Rational combination therapy for the treatment of cancer

Publications (1)

Publication Number Publication Date
BR112018006572A2 true BR112018006572A2 (pt) 2018-10-09

Family

ID=57145064

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018006572A BR112018006572A2 (pt) 2015-10-05 2016-10-05 terapia de combinação racional para o tratamento de câncer

Country Status (14)

Country Link
US (1) US20180280397A1 (enExample)
EP (1) EP3359196B1 (enExample)
JP (1) JP7132848B2 (enExample)
KR (1) KR20180058824A (enExample)
CN (1) CN108472376A (enExample)
AU (1) AU2016336351A1 (enExample)
BR (1) BR112018006572A2 (enExample)
CA (1) CA3000851A1 (enExample)
EA (1) EA201890623A1 (enExample)
IL (1) IL258494A (enExample)
MA (1) MA47474A (enExample)
MX (1) MX2018004112A (enExample)
TW (1) TW201722422A (enExample)
WO (1) WO2017062520A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016008418A (es) 2013-12-23 2017-01-11 Memorial Sloan Kettering Cancer Center Metodos y reactivos para el radiomarcaje.
CN110090303B (zh) * 2019-05-07 2022-09-16 浙江大学 阿片受体激动剂在制造用于治疗恶性肿瘤的药物中的用途
CN112641949A (zh) * 2021-01-11 2021-04-13 深圳市人民医院(深圳市呼吸疾病研究所) 一种含有pi3k抑制剂的药物组合物及其应用
US20240371465A1 (en) * 2023-05-02 2024-11-07 National Central University Method, system, and computer readable medium for post-translational modifications detection
CN116813622B (zh) * 2023-05-19 2026-02-03 中国科学院基础医学与肿瘤研究所(筹) 一种基于分子伴侣hsp90介导的靶向降解gpx4的嵌合体及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004512381A (ja) 2000-11-02 2004-04-22 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｈｓｐ９０インヒビターの使用により細胞毒性剤の効力を増強させる方法
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
ES2645095T3 (es) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Research Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90
NZ623069A (en) 2009-08-17 2015-11-27 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
PT2486039T (pt) 2009-10-07 2016-09-06 Sloan Kettering Inst For Cancer Res Derivados de purina úteis como inibidores de hsp90
AU2012240077C1 (en) 2011-04-05 2017-08-10 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
MX354215B (es) 2011-04-05 2018-02-19 Sloan Kettering Inst Cancer Res Inhibidores de la proteina 90 de choque termico (hsp90).
ES2624982T3 (es) 2011-07-08 2017-07-18 Sloan-Kettering Institute For Cancer Research Usos de inhibidores etiquetados HSP90
KR102319582B1 (ko) 2013-08-16 2021-11-04 메모리얼 슬로안 케터링 캔서 센터 선택적 ｇｒｐ９４ 저해제 및 이의 용도
EA201692155A1 (ru) 2014-05-13 2017-04-28 Мемориал Слоун-Кеттеринг Кэнсэ Сентр МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ

Also Published As

Publication number Publication date
EP3359196B1 (en) 2022-03-16
MA47474A (fr) 2019-12-25
EP3359196A1 (en) 2018-08-15
WO2017062520A1 (en) 2017-04-13
CA3000851A1 (en) 2017-04-13
EA201890623A1 (ru) 2018-09-28
JP7132848B2 (ja) 2022-09-07
MX2018004112A (es) 2018-06-20
JP2018537519A (ja) 2018-12-20
IL258494A (en) 2018-05-31
US20180280397A1 (en) 2018-10-04
KR20180058824A (ko) 2018-06-01
TW201722422A (zh) 2017-07-01
AU2016336351A1 (en) 2018-05-10
CN108472376A (zh) 2018-08-31

Similar Documents

Publication Publication Date Title
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
BR112016004095A2 (pt) administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores
BR112017007765A2 (pt) composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
MX373187B (es) Terapia de combinación para tratar cáncer.
MX392752B (es) Terapia de combinacion para tratar cancer.
BR112017012377A2 (pt) conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula
PE20180260A1 (es) Metodos y kits para tratar la depresion
MX2017013142A (es) Terapia combinada para tratar cáncer.
BR112014031088A8 (pt) métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal
BR112015021115A2 (pt) agentes para induzir apoptose para o tratamento de câncer e doenças imunes e autoimunes
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
BR112019007210A2 (pt) métodos e composições para o tratamento da doença de fabry
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
MX2021014242A (es) Uso de linagliptina en terapia antidiabetica cardio- y renoprotectora.
BR112014018728A8 (pt) Compostos de purinonas como inibidores de quinase
BR112012020558A2 (pt) moduladores do receptor de androgênio e seus usos
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
DOP2012000265A (es) Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores.
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
BR112015023203A2 (pt) métodos para tratamento de câncer, para aumentar a eficiência de um tratamento de câncer, para retardar e/ou prevenir o desenvolvimento de câncer, para tratar um indivíduo com câncer, para aumentar a sensibilidade para um agente de terapia para câncer, para estender um período de sensibilidade e para estender a duração da resposta para uma terapia para câncer, e usos
BR112014026057A2 (pt) análogos limitados por anel como inibidores de arginase
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112015017241A2 (pt) doadores de nitroxil com índice terapêutico melhorado
BR112017018198A2 (pt) inibição da atividade de olig2

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]